Double-hit diffuse large B-cell lymphoma

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3439-3443

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CELL; CASE REPORT; CHROMOSOME TRANSLOCATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENES, BCL-2; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; PROGNOSIS; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 84867044057     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.5800     Document Type: Article

References (31)

1. Friedberg JW, Fisher RI: Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22:941-952, ix, 2008
2. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005 (Pubitemid 46224009)
3. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
4. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
5. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
6. Persky DO, Unger JM, Spier CM, et al: Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26:2258-2263, 2008
7. Friedberg JW: Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol 7:357-359, 2006
8. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
9. Barrans S, Crouch S, Smith A, et al: Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360-3365, 2010
10. Savage KJ, Johnson NA, Ben-Neriah S, et al: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114:3533-3537, 2009
11. Johnson NA, Savage KJ, Ludkovski O, et al: Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 114:2273-2279, 2009
12. Li S, Lin P, Fayad LE, et al: B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14; 18)(q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25:145-156, 2012
13. Pedersen MØ, Gang AO, Poulsen TS, et al: Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma: A single centre's experience. Eur J Haematol 89:63-71, 2012
14. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006 (Pubitemid 43855045)
15. Kluk MJ, Chapuy B, Sinha P, et al: Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 7:e33813, 2012
16. Green TM, Young KH, Visco C, et al: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460-3467, 2012
17. Johnson NA, Slack GW, Savage KJ, et al: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452-3459, 2012
18. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925- 934, 1996
19. Mead GM, Barrans SL, Qian W, et al: A prospective clinicopathologic study of dose-modified CODOXM/ IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:2248-2260, 2008
20. Cuccuini W, Briere J, Mounier N, et al: MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 119: 4619-4624, 2012
21. Pérez-Galán P, Dreyling M, Wiestner A: Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26-38, 2011
22. LaCasce AS, Kho ME, Friedberg JW, et al: Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol 26: 5107-5112, 2008
23. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al: Gene expression profiling and not immunophenotypic algorithms predicts prognosis in patients with DLBCL treated with R-CHOP. Blood 117:4836-4843, 2011
24. Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011:498-505, 2011
25. Dunleavy K, Little RF, Pittaluga S, et al: A prospective study of dose-adjusted EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: A regimen with high efficacy and low toxicity. Ann Oncol 19:iv83, 2008
26. Sasaki N, Kuroda J, Nagoshi H, et al: Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 39:817-828, 2011
27. den Hollander J, Rimpi S, Doherty JR, et al: Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116:1498-1505, 2010
28. Friedberg JW, Mahadevan D, Jung JA, et al: Phase 2 trial of alisertib, an investigational potent inhibitor of aurora a kinase, in patients with aggressive B- and T-cell non Hodgkin lymphoma. Blood 118, 2011 (suppl; abstr 46)
29. Friedberg JW: New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice. Clin Cancer Res 17:6112-6117, 2011
30. Wilson WH, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008
31. Stiff PJ, Unger JM, Cook J, et al: Randomized phase III US/Candadian intergroup trial comparing CHOP +/- R for eight cycles to CHOP +/- R for six cycles followed by autotransplant for patients with high intermediate or high IPI grade diffuse aggressive non Hodgkin lymphoma. J Clin Oncol 29:504s, 2011 (suppl 15; abstr 8001)